Wednesday, October 14, 2026

Venture Capital Shifts $716M from Crypto Holdings to AI Enterprise Software

Institutional investors are rotating capital from cryptocurrency assets—which grew 16% year-over-year to 716 million owners—into AI-enabled enterprise automation and private equity infrastructure plays. Series B funding now concentrates on enterprise automation platforms like Ivo and Nomagic, while specialist VC funds including Outlast and Cogito Capital target AI infrastructure. This mirrors Aswath Damodaran's thesis that AI represents disruptive, not merely instrumental, technology.

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
Venture Capital Shifts $716M from Crypto Holdings to AI Enterprise Software
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Venture capital firms are reallocating $716 million from cryptocurrency holdings into AI-driven enterprise software, marking a sector-wide shift in institutional capital deployment. Crypto ownership expanded 16% year-over-year to 716 million holders, yet investors are diversifying beyond digital assets.

Series B financing rounds now concentrate on enterprise automation startups. Ivo and Nomagic secured funding for workplace automation platforms, while specialist funds Outlast and Cogito Capital raised capital specifically for AI infrastructure investments. The activity suggests institutional conviction that AI warrants structural portfolio reweighting.

NYU Stern professor Aswath Damodaran's recent analysis frames AI as disruptive technology comparable to Nvidia's semiconductor dominance, not just an incremental productivity tool. His valuation framework treats AI capabilities as market-transforming assets, justifying concentrated capital allocation rather than diversified tech exposure.

Private equity deployment follows the same pattern. Firms are backing AI-enabled business process platforms over blockchain infrastructure, betting enterprise customers will pay premiums for automation that cuts headcount costs. Hudson Talent Solutions launched TalentIQ and Hudson Flow, agentic AI products for recruitment process outsourcing, capturing $11.1 million in new client gross profit over four quarters.

The rotation accelerates despite crypto's user base growth. Institutional funds view AI enterprise software as offering clearer revenue models and faster paths to profitability than cryptocurrency ventures, which face regulatory uncertainty and volatile token valuations.

Energy sector investors also pivot to AI infrastructure. Drilling service providers see automation software as higher-margin than equipment sales, even as natural gas and geothermal drilling expand. One energy services firm reported $1 million adjusted EBITDA on $3.7 million revenue in Q3 2025, targeting AI-driven operational efficiency tools.

Building materials companies follow suit. Timber Technologies and KBS completed automation projects in modular construction, applying machine learning to workplace housing and commercial builds. Their backlog reached $20 million in committed orders with a 1.01 book-to-bill ratio over 12 months.

This capital reallocation reflects investor belief that AI will restructure enterprise operations within 24 months, making early-stage positioning critical. Funds that waited on crypto adoption now move preemptively on AI infrastructure, unwilling to repeat slow entry timing.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· January 6, 2026
    Charlie Munger once said you can ‘ease off the gas’ when you reach this money milestone, and Mark Tilbury agrees
  2. [2]News articleYahoo Finance· December 23, 2025
    Fan Tokens and the Road to 2026: Assessing the Opportunity
  3. [3]News articleYahoo Finance· January 27, 2026
    Star Equity (STRR) Q3 2025 Earnings Transcript
  4. [4]News articleYahoo Finance· January 27, 2026
    Star Equity (STRR) Q4 2024 Earnings Transcript
  5. [5]News articleNasdaq· January 6, 2026
    The Motley Fool Interviews NYU Professor Vasant Dhar: Thinking With Machines
  6. [6]News articleYahoo Finance· December 30, 2025
    12 investors dish on what 2026 will bring for climate tech
  7. [7]Press releaseGlobeNewswire· February 17, 2026
    13,000 strong: AIBC Eurasia 2026 sets the stage for a bigger 2027
  8. [8]Press releaseGlobeNewswire· February 17, 2026
    Basilea erzielt starke Ergebnisse im Geschäftsjahr 2025 und übertrifft Umsatz- und Betriebsgewinn-Guidance
  9. [9]News articleYahoo Finance· February 13, 2026
    DSV, 1166 - NOTICE OF ANNUAL GENERAL MEETING 2026
  10. [10]News articleYahoo Finance· February 19, 2026
    Renault Group demonstrates its resilience, the robustness of its strategy, and moves forward with confidence
  11. [11]News articleYahoo Finance· December 9, 2025
    Stock market today: Dow and S&P 500 slip, Nasdaq rises as Fed meeting kicks off, JOLTS data shows openings rose
  12. [12]Press releaseGlobeNewswire· February 18, 2026
    The Vita Coco Company Reports Fourth Quarter and Full Year 2025 Financial Results
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com